Skip to main content
Year archive

argenx SE — 2025 filings

All 59 regulatory filings released by argenx SE (1AE) in 2025, sourced directly from the official regulator.

59 Filings
2025 Period
2025 filings (59)
Filing Released Lang
FORM S-8
Registration Form
2025-12-17 English
FORM 6-K
Foreign Filer Report
2025-12-15 English
argenx Provides Update on UplighTED Studies of Efgartigimod SC in Thyroid Eye Disease
Regulatory Filings
2025-12-15 English
argenx Announces Results of Extraordinary General Meeting of Shareholders
Declaration of Voting Results & Voting Rights Announcements
2025-11-19 English
FORM 6-K
Foreign Filer Report
2025-11-18 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-11-14 English
6-K
Foreign Filer Report
2025-10-30 English
argenx Reports Third Quarter 2025 Financial Results and Provides Business Update
Earnings Release Q3 2025
2025-10-30 English
argenx Presents New Data at AANEM and MGFA Highlighting the Strength and Broad Benefit of VYVGART for Myasthenia Gravis Patients
Audit Report / Information Q4 2025
2025-10-30 English
FORM 6-K
Foreign Filer Report
2025-10-29 English
argenx to Report Third Quarter 2025 Financial Results and Business Update on October 30, 2025
Report Publication Announcement
2025-10-23 English
FORM 6-K
Foreign Filer Report
2025-10-15 English
argenx to Highlight Key Data and Breadth of Immunology Innovation at 2025 AANEM Annual Meeting and MGFA Scientific Session
Regulatory Filings
2025-10-15 English
argenx announces Extraordinary General Meeting of Shareholders on November 18, 2025
AGM Information
2025-10-06 English
FORM 6-K
Foreign Filer Report
2025-10-03 English
argenx to Present at Upcoming Investor Conferences
Report Publication Announcement
2025-08-28 English
FORM 6-K
Foreign Filer Report
2025-08-25 English
argenx Announces Positive Topline Results from ADAPT SERON Study of VYVGART in Patients with AChR-Ab Seronegative gMG
Earnings Release Q3 2025
2025-08-25 English
argenx to Host R&D Webinar Highlighting ARGX-119 on September 16, 2025
Regulatory Filings
2025-08-19 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-08-14 English
argenx and Tennis Legend Monica Seles Team Up to Raise Awareness of Myasthenia Gravis
Regulatory Filings
2025-08-12 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-08-12 English
6-K
Foreign Filer Report
2025-07-31 English
argenx Reports Half Year 2025 Financial Results and Provides Second Quarter Business Update
Earnings Release H1 2025
2025-07-31 English
argenx SE, Halfjaarlijkse financiële verslaggeving
Interim / Quarterly Report H1 2025
2025-07-31 English
argenx to Report Half Year 2025 Financial Results and Second Quarter Business Update on July 31, 2025
Report Publication Announcement
2025-07-24 English
FORM 6-K
Foreign Filer Report
2025-06-30 English
argenx Advances Clinical Development of ARGX-119 in Congenital Myasthenic Syndromes
Earnings Release Q2 2025
2025-06-30 English
argenx Announces European Commission Approval of VYVGART Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy
Regulatory Filings
2025-06-23 English
FORM 6-K
Foreign Filer Report
2025-06-20 English
FORM 6-K
Foreign Filer Report
2025-06-11 English
argenx Presents New Efgartigimod Data at EULAR 2025 Highlighting Positive Phase 2 Proof-of-Concept Results in Myositis and Sjogren’s Disease
Earnings Release Q2 2025
2025-06-11 English
argenx to Present at Goldman Sachs 46th Annual Global Healthcare Conference
Regulatory Filings
2025-06-03 English
argenx Announces Results of Annual General Meeting of Shareholders
Declaration of Voting Results & Voting Rights Announcements
2025-05-29 English
FORM 6-K
Foreign Filer Report
2025-05-28 English
6-K
Foreign Filer Report
2025-05-08 English
argenx Reports First Quarter 2025 Financial Results and Provides Business Update
Earnings Release Q1 2025
2025-05-08 English
argenx to Present at BofA Securities 2025 Health Care Conference
Regulatory Filings
2025-05-06 English
argenx to Report First Quarter 2025 Financial Results and Business Update on May 8, 2025
Report Publication Announcement
2025-05-01 English
FORM 6-K
Foreign Filer Report
2025-04-28 English
argenx Announces Positive CHMP Opinion for VYVGART (efgartigimod alfa) Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Regulatory Filings
2025-04-28 English
argenx Announces Annual General Meeting of Shareholders on May 27, 2025
Proxy Solicitation & Information Statement
2025-04-16 English
FORM 6-K
Foreign Filer Report
2025-04-12 English
FORM 6-K
Foreign Filer Report
2025-04-11 English
FORM 6-K
Foreign Filer Report
2025-04-08 English
argenx Highlights VYVGART Data at AAN 2025 Setting New Standard in Sustained Efficacy and Improved Quality of Life Measures for Patients Living with gMG and CIDP
Regulatory Filings
2025-04-08 English
20-F
Annual Report FY 2024
2025-03-20 English
6-K
Foreign Filer Report
2025-03-20 English
argenx SE, Jaarlijkse financiële verslaggeving
Annual Report (ESEF) FY 2024
2025-03-20 English
FORM 6-K
Foreign Filer Report
2025-03-07 English
argenx Highlights FcRn Leadership with Long-term Data and Transformational Patient Outcomes at the American Academy of Neurology 2025 Annual Meeting
Environmental & Social Information
2025-03-07 English
6-K
Foreign Filer Report
2025-02-27 English
argenx Reports Full Year 2024 Financial Results and Provides Fourth Quarter Business Update
Earnings Release FY 2024
2025-02-27 English
argenx to Present at TD Cowen 45th Annual Healthcare Conference
Regulatory Filings
2025-02-25 English
argenx to Report Full Year 2024 Financial Results and Fourth Quarter Business Update on February 27, 2025
Report Publication Announcement
2025-02-20 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-02-12 English
FORM 6-K
Foreign Filer Report
2025-01-13 English
argenx Highlights 2025 Strategic Priorities
Earnings Release FY 2024
2025-01-13 English
argenx to Present at 43rd Annual J.P. Morgan Healthcare Conference
Investor Presentation
2025-01-06 English